Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
The present invention is directed to compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved
patent: 5200412 (1993-04-01), Whittaker et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6166063 (2000-12-01), Villhauer
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6699871 (2004-03-01), Edmondson et al.
patent: 7125873 (2006-10-01), Edmondson et al.
patent: 2006/0052382 (2006-03-01), Duffy et al.
patent: 2006/0270679 (2006-11-01), Edmondson et al.
patent: WO 02/076450 (2002-10-01), None
patent: WO 03/000180 (2003-01-01), None
patent: WO 03/000181 (2003-01-01), None
patent: WO 03/004498 (2003-01-01), None
http://en.wikipedia.org/wiki/Atherosclerosis, p. 1-3 of 3.
http://en.wikipedia.org/wiki/Retinopathy, p. 1 of 2, 1 page.
Wiedeman et al., “Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome”, Drug Discovery Today: Therapeutic Strategies, 2005, vol. 2, p. 143-149.
McIntosh et al., “Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?”, Regulatory Peptides, 128 (2005), 159-165.
Ahren et al., “Inhibition of Dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes”, The Journal of Clinical Endocrinology & metabolism, 89(2): 2078-2084.
http://en.wikipedia.org/wiki/Hyperglycemia, p. 1-2 of 4, 2 pages enclosed.
http://en.wikipedia.org/wiki/Diabetes—mellitus—type—1, p. 1 of 6, 1 page enclosed.
Augeri et al., “Discovery and Preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes”, J. Med. Chem. 2005, 48, 5025-5037.
http://dictionary.reference.com/browse/prophylaxis, p. 2 of 4, 1 page enclosed.
http://www.webmd.com/hypertension-high-blood-pressure/guide/preventing-high-blood pr..., p. 1-2 of 2.
http://www.webmd.com/diet/tc/Obesity-Overview, p. 1-2 of 3, 2 pages enclosed.
http://diabetes.webmd.com/guide/insulin-resistance syndrome, p. 1 of 1.
http://diabetes.webmd/guide/preventing-type-2-diabetes,.p. 1-2 of 3, 2 pages enclosed.
Erez et al., “The rationale for using HMG-CoA reductase inhibitors (‘statins’) in peripheral arterial disease”, Eur. J. Vasc. Endovasc. Surg., 33, 192-201 (2007).
Rieusset et al., A New Selective Peroxisome Proliferator-Activated Receptor gamma Antagonist with Antiobesity and Antidiabetic Activity, abstract (pp. 1 and 2 of 6), 2 pages enclosed.
He et al., Adipose-specific peroxisome proliferator-activated receptor (gamma) knockout causes insulin resistance in fat and liver but not in muscle, PNAS, vol. 100, No. 26, pp. 15712-15717.
Ryan et al., PPAR gamma Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice, abstract (pp. 1 and 2 of 4), 2 pages enclosed.
Hung et al., Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance, abstract (pp. 1 and 2 of 3), 2 pages enclosed.
Chapman, J. M., “Therapeutic Elevation of HDL-cholesterol to prevent atherosclerosis and coronary hear disease”, Pharmacology and Therapeutics, 111 (2006), 893-908.
Daniel J. Drucker, “Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes”, Expert Opinion on Investigational Drugs, 2003, pp. 87-100, vol. 12, Issue 1.
Koen Augustyns et al., , “Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes”, Expert Opinion on Therapeutic Patents, 2003, pp. 499-510, vol. 13, Issue 4.
Carolyn F. Deacon et al., “Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?”, Expert Opinion on Investigational Drugs, 2004, pp. 1091-1102, vol. 13, Issue 9.
Novartis AG, Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidyl peptidase IV in the treatment of non-insulin-dependent diabetes mellitus:, Expert Opinion on Therapeutic Patents, 2000, pp. 1937-1942, vol. 10, Issue 12.
Brockunier Linda L.
Duffy Joseph L.
Parmee Emma R.
Weber Ann E.
Durette Philippe L.
Fitch Catherine D.
Loewe Sun Jae Y
Merck & Co. , Inc.
β-amino heterocyclic dipeptidyl peptidase inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.If you have personal experience with β-amino heterocyclic dipeptidyl peptidase inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β-amino heterocyclic dipeptidyl peptidase inhibitors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3880928